Smartphone App Study to Assess How Trikafta Affects Daily Life

Smartphone App Study to Assess How Trikafta Affects Daily Life

295787

Smartphone App Study to Assess How Trikafta Affects Daily Life

A first-of-its-kind, observational study will allow patients with cystic fibrosis (CF) to use their smartphones to monitor the ways in which Trikafta (elexacaftor/tezacaftor/ivacaftor) affects their daily lives. Sponsored by the Cystic Fibrosis Foundation, the now-enrolling HERO-2 study (NCT04798014) will collect patients’ self-reported feedback for one year to track changes in their daily medications and symptoms while taking Trikafta. Participants will be also asked to report instances of changes to their treatment plan and pulmonary exacerbations (the…

You must be logged in to read/download the full post.